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Abstract A 6-year-old girl was admitted to our hospital for
excessive weight gain. On presentation, she had a typical
Cushingoid appearance and hypertension. Laboratory analysis
was indicative for an exogenous glucocorticoid source,
showing values that were low for serum cortisol and
adrenocorticotropin and for 24-h urinary glucocorticoid
(metabolite) excretion. Five and 2 months before presentation,
she was treated with intradermal triamcinolone acetonide for
keloid scars. Recovery of intrinsic cortisol production occurred
12 months after the last steroid dose. Intradermal triamcino-
lone acetonide for keloid scars in children should be used with
care taking into account the here reported complication.
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Introduction
Long-term glucocorticoid treatment is known to cause
Cushing's syndrome and adrenal insufficiency. Here, we
present a child who developed these conditions after two
treatment courses with normal amounts of triamcinolone
acetonide (TCA) administered intradermally in another
hospital for keloid scars. As the parents were reassured
that this treatment was without any side effects, they did not
mention it instantly when their daughter was evaluated in
our center for excessive weight gain a few months later.
Case report
A 6-year-old previously healthy girl was seen at our outpatient
department because of excessive weight gain (3 kg in the past
3 months), despite a virtually normal intake and unchanged
physical exercise according to the parents. There was no
medication use. Height development in infancy and childhood
had always been around the 50th percentile. All family
members were in good health, except for an older brother who
had undergone a bone marrow transplantation a few years ago
because of homozygous beta-thalassemia.
On physical examination, she had a moon face (Fig. 1), a
central pattern of fat distribution, and a blood pressure of
118/85 mmHg (both >95th percentile). There were (remains
of) keloid scars in the lower abdominal region and in the
left loin (2% to 3% of her body surface area), which had
appeared after a hot water burn. Her height was 117.3 cm
(−0.1 SD), and her weight was 24.4 kg (+1.3 SD).
Laboratory tests showed a normal thyroid function.
Serum cortisol and adrenocorticotropin (ACTH), which
were measured in the morning after overnight fasting, were
below detection limits (normal 0.100–0.600 µmol/l and 15–
75 ng/l, respectively). Sodium, potassium, and glucose
were all normal. Urinary free cortisol excretion was 5 nmol/
24 h (normal 55–220 nmol/24 h). Glucocorticoid metabo-
lites in 24-h urine obtained on one occasion were
undetectable. Salivary cortisol levels were low, and diurnal
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rhythmicity was absent. These laboratory findings were
indicative for an exogenous glucocorticoid source.
Accidental steroid exposure was unlikely, since there
was no glucocorticoid use for post-bone marrow transplan-
tation by her older brother. Steroid use by the other family
members was also reported to be negative. Subsequently,
the parents were asked to describe their daughter’s medical
history in detail. They told that in another hospital,
injections had been given into the keloid scars on two
occasions. Information retrieved from that hospital revealed
that 5 months prior to the initial presentation, she was
treated with 160 mg of TCA, and 2 months before the first
visit, she was given 40 mg of TCA in spite of concerns by
the parents of increasing puffiness.
Ten months after the first injection, serum levels of
cortisol and ACTH, obtained in the morning, were
0.090 μmol/l and 18 ng/l, respectively. Continuing sup-
pression of the hypothalamus-pituitary-adrenal axis was
subsequently confirmed with a low-dose ACTH test
(tetracosactide 1 µg per 1.73 m2 body surface area), during
which, the serum cortisol level rose from 0.040 to
0.190 μmol/l. Cushingoid features became less apparent
13 months after the first injection. At the same time, it was
noted that height velocity, which had dramatically declined
since the first presentation, had started to increase again.
Fifteen months after the first injection, the hypothalamus-
pituitary-adrenal axis had finally recovered: cortisol in-
creased from 0.103 to 0.538 μmol/l during the low-dose
ACTH test. Until recovery of intrinsic cortisol production
had occurred, the parents were instructed to give hydrocor-
tisone in case of febrile illnesses or moderate injury.
Discussion
Cushing syndrome is caused by excessive circulating
cortisol levels and is characterized by a changed facial
appearance, abdominal fat deposition, muscle weakness,
striae, hirsutism, insulin resistance, and hypertension.
Pediatric Cushing’s syndrome is caused by ACTH produc-
ing pituitary adenoma (Cushing’s disease) in 75–80% of
cases [7]. The median age of these patients is 14 years. Less
frequent are adrenocortical tumors or other causes leading
to hypercortisolism, such as the ectopic ACTH syndrome or
adrenal hyperplasia secondary to McCune–Albright syn-
drome. There are no quantitative data available as to which
extent synthetic steroids contribute to the incidence of
Cushing's syndrome in the pediatric age range.
In this report, we describe a 6-year-old child who
developed Cushing’s syndrome after intradermal injections
with TCA. Triamcinolone is a synthetic steroid which
differs from cortisol mainly in 9-alpha fluoridation. Due to
this chemical structure, it acts as a potent glucocorticoid.
The anti-inflammatory effect of triamcinolone is five times
as potent as that of endogenous cortisol. Contrary to
cortisol, it has no affinity for the mineralocorticoid receptor.
So, the hypertension observed in our patient had resulted
from glucocorticoid receptor-mediated effects on the vas-
cular tone rather than from mineralocorticoid receptor-
driven sodium retention. She was treated with 200 mg of
TCA. This dose is equal to only 3 months of intrinsic
cortisol production (at a mean rate of 12 mg/m2/24 h).
Comparable steroid doses are often given for an acute
asthma exacerbation [8].
It has been tested in a sample of 22 children with chronic
arthritis that suppression of intrinsic cortisol production,
assessed by salivary cortisol concentration, may last 10 to
30 days after an intra-articular injection with triamcinolone
hexacetonide (THA) [2]. None of the children in this group
had developed a Cushingoid state. In contrast, Cushing’s
syndrome after intra-articular TCA has been described by
several reports in adults [3, 5] and children [1, 4]. A
retrospective analysis comparing TCA with THA in
children with juvenile idiopathic arthritis showed that 5%
Fig. 1 Facial appearance of our patient. a Just before TCA treatment. b Six months after the first TCA dose
1148 Eur J Pediatr (2010) 169:1147–1149
had developed a Cushingoid appearance after intra-articular
TCA, whereas nobody had developed this after THA [1].
For our patient, it is conceivable that the keloid scars
might have served as a “slow release reservoir,” probably
due to poor absorption and vascularization locally. A mild
manifestation of Cushing’s syndrome has been described in
two children who were treated with TCA for post-burn
hypertrophic scars [6]. To date, Cushing’s syndrome with
prolonged adrenal suppression has been described in two
children who were treated with TCA for keloid scars [4, 9].
One of these patients had received 500–600 mg of TCA [4],
while the other had received only 40 mg of TCA [9]. In
these patients, adrenal suppression was still present 8 to
9 months after intralesional TCA injection, but recovery of
intrinsic cortisol production was not reported by the papers.
In our patient, adrenal suppression was present up to
15 months after the first steroid dose. Suppression of
intrinsic cortisol production is potentially fatal under
circumstances where the physiological demand for cortisol
exceeds the ability of the adrenal glands to produce it, such
as febrile illnesses, trauma, or surgery.
TCA should be used with care for keloid scars in children,
now evidence is accumulating that even a relatively low dose
of intradermal TCA may elicit Cushing’s syndrome and
prolonged adrenal suppression. We recommend that TCA
should not be part of the routine treatment of keloid scars in
children. TCA should only be considered in case of
problematic keloid scars (e.g., severe cosmetic problems or
contractures).
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